Target intelligence / Profile preview

DNA polymerase 3′–5′ exonuclease (3′–5′ Exo)

Target
3′–5′ Exo
Molecular classification
Enzyme, Hydrolase, DNA-directed DNA polymerase subunit, Exonuclease
01

Overview

DNA polymerase 3′–5′ exonuclease activity, commonly known as the proofreading function, is a critical enzymatic process primarily associated with high-fidelity DNA polymerases such as Polymerase Epsilon (POLE) and Polymerase Delta (POLD1) (UniProt P27677, P28907). This activity ensures genomic integrity by identifying and removing mispaired nucleotides at the 3' end of a growing DNA strand before further elongation proceeds, thereby reducing the error rate of DNA replication by several orders of magnitude. In a clinical context, germline or somatic mutations within the exonuclease domain of these polymerases lead to a loss of proofreading capability, resulting in an 'ultramutated' genomic profile and a strong predisposition to various cancers, most notably colorectal and endometrial malignancies (Heitzer & Tomlinson, 2014; PubMed 24870022). While not a traditional drug target in the sense of a receptor, this activity is a major determinant of sensitivity to nucleoside analog chemotherapies, as the exonuclease can excise these drugs from the DNA, leading to resistance. Furthermore, the loss of this activity serves as a potent biomarker for the efficacy of immune checkpoint inhibitors like pembrolizumab, as the resulting high mutation burden generates numerous neoantigens that trigger a robust anti-tumor immune response (Rayner et al., 2016; PubMed 26823170).

Other names
Proofreading domainDNA polymerase proofreading activity3'-5' exonuclease domainDNA-directed DNA polymerase exonucleasePOLE exonuclease domainPOLD1 exonuclease domain
02

Mechanism of action

The 3′–5′ exonuclease activity provides a proofreading mechanism that removes misincorporated or damaged nucleotides from the 3' terminus of the nascent DNA strand during replication. Therapeutic strategies involve either exploiting the loss of this activity (using immune checkpoint inhibitors for ultramutated tumors) or potentially inhibiting the activity to prevent the excision of therapeutic nucleoside analogs, thereby enhancing their cytotoxic effect by ensuring they remain incorporated in the DNA.

03

Biological functions

DNA replicationDNA repairGenome stabilityProofreadingMaintenance of replication fidelity
04

Disease associations

CancerPolymerase Proofreading-Associated Polyposis (PPAP)Colorectal cancerEndometrial cancerHypermutation syndromes
05

Safety considerations

Increased risk of de novo mutationsGenomic instabilityPotential for secondary malignanciesAcquired resistance to nucleoside analogs through exonuclease upregulation
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

POLE exonuclease domain mutationPOLD1 exonuclease domain mutationTumor Mutational Burden (TMB)Ultramutated phenotypeMicrosatellite stability (MSS) with high TMB

Beyond the preview

Go deeper on DNA polymerase 3′–5′ exonuclease (3′–5′ Exo).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase 3′–5′ exonuclease (3′–5′ Exo).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call